How this company measures up on the fundamentals that matter
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $18 against a fair value of $40, a 55% discount. Fails ethical screen (Debt ratio). Ranks better than 64% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-05 | MCDONNELL MICHAEL R | Director | 12,836 | — | |
| 2026-05-05 | WILKES DAVID S. M.D. | Director | 12,836 | — | |
| 2026-05-05 | AMPOFO WILLIAM A. II | Director | 12,836 | — | |
| 2026-05-05 | WENDELL AMY MCBRIDE | Director | 12,836 | — | |
| 2026-05-05 | SHAFER DAVID BRENT | Chairman of the Board | 12,836 | — | |
| 2026-05-05 | SCHLICHTING NANCY M | Director | 12,836 | — | |
| 2026-05-05 | CRAIG JEFFREY A | Director | 12,836 | — | |
| 2026-05-05 | MORRISON PATRICIA B | Director | 12,836 | — | |
| 2026-02-27 | ROSENBLOOM DAVID S | General Counsel | 26,709 | — | |
| 2026-02-27 | HIDER ANDREW P | Chief Executive Officer | 201,804 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Sale | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31